14th Oncology Update: Advances and Controversies
Steamboat Springs, Colorado
January 15-19, 2016
She's not stopping.
A Laughable piece! Can't beleive that is professional journalism, biotech expertise material. Neuvax will likely fail because of history!! Not science, but history of cancer vaccine failures. Wow! Brilliant piece! Bravo MF. Bravo. Does this dude no anything about the trial? Plain ignorance. What an ignorant dude.
Expert Rev Anticancer Ther. 2015 Sep 10:1-8. [Epub ahead of print]
Breast cancer and immunology: biomarker and therapeutic developments.
Santa-Maria CA1, Park SJ2, Jain S3, Gradishar WJ3.
While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.
This is significant. Definately GALE would not have a) submitted something negative b) roll out PRs early on.
This is pre-third quarter. I think this can be the start of something fun. Let's not forget that E.Mittendorf has NOT backed down from her présentations.
You may have noticed that some of his stories, especially from ASCO 2015, seem to have had help from the mouths of the pharma communication's dept. Not convinced he's capable of writing detailed trial analyses as he writes, on his own.........my opinion.....
Many scientific articles on the topic. Here's one.
Clin Adv Hematol Oncol. 2015 Jun;13(6):372-82.
Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
Gingras I1, Azim HA Jr1, Ignatiadis M1, Sotiriou C1.
Every cancer triggers an immune response that constitutes an important first-line protection against cancer progression. In breast cancer, there is an increasing awareness of the relationship between the immune system and tumor evolution. The tumor microenvironment is composed of a variety of immune cells that can control or arrest malignant progression. Chemotherapy and targeted therapy have been shown to modulate this immune microenvironment. Recently, tumor-infiltrating lymphocytes have emerged as a predictive and prognostic biomarker in early breast cancer. In addition, immune gene expression signatures have been shown to be associated with prognosis in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Such findings have increased interest in the development of immunotherapeutic agents for breast cancer, and multiple clinical trials of anticancer vaccines and immune checkpoint inhibitors are ongoing. In this review, we summarize what is known about the relationship between immunity and breast carcinoma, explore the relevance of this information to the clinical and research settings, and give a portrait of new therapeutic strategies using immunotherapy in breast cancer.
Vaccine. 2015 Oct 2. pii: S0264-410X(15)01376-6. doi: 10.1016/j.vaccine.2015.09.086.
Cancer vaccines in the new era of cancer immunotherapy.
Knutson KL1, Mittendorf EA2.
Message I got back in July:
The European CanCer Organisation (ECCO) will release abstracts for general viewing, provided authors have consented, on its website on 11 September 2015. Abstracts where authors did not consent to early release will be published online on the first day of the Congress, 25 September 2015.
Abstracts selected for oral presentations and late-breaking abstracts will only be released for general viewing on the ECCO website on the day of their respective presentations.
Exciting times ahead! LONG GALE
Thanks Dan for your reporting. It's all good info. Nothing negative. This is cancer research- long-term. Did you ask Dr M when/where her next presentation on immunotherapy would be?
Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis
Not an easy disease state to treat. One more study needed.
A personal vendetta against GALE. Basically, editors/owners feel they lost credibility with dream-team and M. Ahn. Now, they will do anything to pay back. This is still not a good reason to have poor journalistic ethics. -----------Vendetta, pure and simple--------------------
MF is on a vendetta binge. Simple. He rehashes same old stuff and gets paid for it. Just words. No
Unfortunately, he has a plateform - a so called journalistic plateform - that allows him to say, what MF wants to say, freely. Plain POOR journalism. Unacceptable financial journalism. Useless. He has a mandate to write 1-2 articles a month on GALE - so obvious.
Totally agree. Scam to unload their shares. Unreal. Unreal.
Synta is garbage, I guess. Useless.
Take my losses. Move on.
Biotechnol Adv. 2015 Oct 30. pii: S0734-9750(15)30048-3. doi: 10.1016/j.biotechadv.2015.10.013.
Peptide vaccines in breast cancer: The immunological basis for clinical response.
This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax - E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.
good find! They are building their team! Very interesting timing.
What should we expect at this conference? Should we expect a PR that day from GALE? Is there a way we can obtain a summary of her presentation on Sept 29th? Anyways, food for thought. Exciting times ahead!!
"This presentation will focus of the clinical trials evaluating NeuVax, a peptide vaccine comprised of the immunogenic epitope E75 and the immunoadjuvant GM-CSF. An update on the ongoing phase III registration trial will be presented."